title: Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer.
abstract: BACKGROUND
  Measurement of tumor response by standard response criteria is challenging in thymic malignancies, especially when the pleura is involved, as it often is in stage IV disease. In this study, we aimed to determine the effectiveness of volumetric response evaluation criteria in solid tumors (volumetrics) for evaluating response in patients with thymic malignancies treated on a phase II study of belinostat.
  
  
  METHODS
  We evaluated the tumor responses of 25 patients with thymic cancer using computed tomography-based RECIST, World Health Organization (WHO), modified RECIST, and volumetrics. As a control, we assessed 37 patients with non-small cell lung cancer (NSCLC) with RECIST and volumetrics.
  
  
  RESULTS
  Agreement analyses in 23 patients with thymic cancer at the time of RECIST-determined progressive disease (PD) compared volumetrics with RECIST, modified RECIST, and WHO criteria. Use of volumetrics was associated with 22% discordance compared with RECIST, 15% versus modified RECIST, and 22% versus WHO criteria. Volumetrics revealed PD 72 days earlier than RECIST (p = 0.016). In another cohort of 35 patients with NSCLC, there was 9% discordance between volumetrics and RECIST at the time of PD. Volumetrics demonstrated PD 32 days earlier than RECIST in NSCLC (p = 0.0078).
  
  
  CONCLUSIONS
  Our study suggests that volumetrics might improve detection of PD. Prospective evaluation of this technique in a larger series of patients with thymic malignancies will be required.
authors: Medical Oncology Branch, Center for Cancer Research, NCI, Bethesda, MD, USA.
authors: Jeremy
authors: J
authors: Force
authors: Arun
authors: A
authors: Rajan
authors: Eva
authors: E
authors: Dombi
authors: Seth M
authors: SM
authors: Steinberg
authors: Giuseppe
authors: G
authors: Giaccone
references: Eur J Cancer. 2009 Jan;45(2):228-47
references: 19097774
references: J Thorac Cardiovasc Surg. 1998 Feb;115(2):310-7; discussion 317-8
references: 9475525
references: Curr Treat Options Oncol. 2008 Dec;9(4-6):277-87
references: 19381821
references: Clin Cancer Res. 2011 Mar 1;17(5):1190-9
references: 21224376
references: Eur J Cancer. 2009 Jan;45(2):248-60
references: 19095437
references: N Engl J Med. 2009 Dec 3;361(23):2221-9
references: 19955524
references: Comput Med Imaging Graph. 2004 Jul;28(5):257-65
references: 15249071
references: Br J Radiol. 2000 Nov;73(875):1178-84
references: 11144795
references: J Thorac Oncol. 2010 Jun;5(6):879-84
references: 20421814
references: Ann Oncol. 2004 Feb;15(2):257-60
references: 14760119
references: J Thorac Cardiovasc Surg. 2009 Jul;138(1):26-31
references: 19577051
references: Cancer. 1981 Jan 1;47(1):207-14
references: 7459811
references: J Clin Oncol. 2010 Mar 10;28(8):1322-8
references: 20124176
references: J Natl Cancer Inst. 1999 Mar 17;91(6):523-8
references: 10088622
references: Neuro Oncol. 2006 Jan;8(1):38-46
references: 16443946
references: Lung Cancer. 2005 Jul;49 Suppl 1:S37-40
references: 15950799
references: Eur J Radiol. 2010 Apr;74(1):130-5
references: 19268516
references: J Clin Oncol. 2001 Jan 15;19(2):551-7
references: 11208850